- Home
- ZYME vs BHK Comparison
ZYME vs BHK Comparison
Compare ZYME & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- BHK
- Stock Information
- Founded
- ZYME 2003
- BHK 2001
- Country
- ZYME United States
- BHK United States
- Employees
- ZYME N/A
- BHK N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- BHK Finance Companies
- Sector
- ZYME Health Care
- BHK Finance
- Exchange
- ZYME Nasdaq
- BHK Nasdaq
- Market Cap
- ZYME 751.6M
- BHK 609.2M
- IPO Year
- ZYME 2017
- BHK N/A
- Fundamental
- Price
- ZYME $13.23
- BHK $10.69
- Analyst Decision
- ZYME Buy
- BHK
- Analyst Count
- ZYME 6
- BHK 0
- Target Price
- ZYME $18.83
- BHK N/A
- AVG Volume (30 Days)
- ZYME 416.1K
- BHK 188.3K
- Earning Date
- ZYME 10-31-2024
- BHK 01-01-0001
- Dividend Yield
- ZYME N/A
- BHK 8.34%
- EPS Growth
- ZYME N/A
- BHK N/A
- EPS
- ZYME N/A
- BHK 1.03
- Revenue
- ZYME $62,199,000.00
- BHK N/A
- Revenue This Year
- ZYME $21.53
- BHK N/A
- Revenue Next Year
- ZYME N/A
- BHK N/A
- P/E Ratio
- ZYME N/A
- BHK $10.42
- Revenue Growth
- ZYME N/A
- BHK N/A
- 52 Week Low
- ZYME $7.97
- BHK $9.02
- 52 Week High
- ZYME $17.70
- BHK $11.09
- Technical
- Relative Strength Index (RSI)
- ZYME 42.19
- BHK 30.32
- Support Level
- ZYME $12.43
- BHK $11.16
- Resistance Level
- ZYME $14.10
- BHK $11.29
- Average True Range (ATR)
- ZYME 0.63
- BHK 0.10
- MACD
- ZYME -0.10
- BHK -0.02
- Stochastic Oscillator
- ZYME 26.50
- BHK 1.21
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.